☆ 4.7 Article

Impaired humoral responses to COVID-19 vaccination in patients with lymphoma receiving B-cell-directed therapies

BLOOD (2021)

Related references

Note: Only part of the references are listed.

Article Multidisciplinary Sciences

Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection

Jennifer M. Dan et al.

Summary: Different components of immune memory to SARS-CoV-2 exhibit distinct kinetics, with antibodies and spike-specific memory B cells remaining relatively stable over 6 months, while CD4(+) T cells and CD8(+) T cells declining with a half-life of 3 to 5 months after infection.

SCIENCE (2021)

Add to Collection

Article Cell Biology

Enhanced SARS-CoV-2 neutralization by dimeric IgA

Zijun Wang et al.

Summary: The IgA response to SARS-CoV-2 was characterized in a cohort of 149 convalescent individuals after COVID-19 diagnosis. IgA responses in plasma generally correlated with IgG responses, and B cells producing IgM, IgG, and IgA were derived from common progenitor cells. Notably, IgA dimers were found to be 15 times more potent than IgA monomers against SARS-CoV-2, suggesting their potential value for protection and vaccine efficacy.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Cell Biology

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Delphine Sterlin et al.

Summary: The study found that humoral immune responses to SARS-CoV-2 infection are dominated by IgA antibodies, with specific IgA plasmablasts rapidly expanding shortly after symptom onset and peaking in the third week of the disease. Virus-specific antibody responses include IgG, IgM, and IgA, with IgA playing a greater role in virus neutralization compared to IgG.

SCIENCE TRANSLATIONAL MEDICINE (2021)

Add to Collection

Article Hematology

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

Yair Herishanu et al.

Summary: Patients with chronic lymphocytic leukemia have a significantly impaired antibody response to the BNT162b2 mRNA COVID-19 vaccine, which is influenced by disease activity and treatment.

BLOOD (2021)

Add to Collection

Letter Hematology

Low neutralizing antibody responses against SARS-CoV-2 in older patients with myeloma after the first BNT162b2 vaccine dose

Evangelos Terpos et al.

BLOOD (2021)

Add to Collection

Article Immunology

Treatment of B-cell depleted COVID-19 patients with convalescent plasma and plasma-based products

Ariel Kenig et al.

Summary: This study demonstrates the therapeutic efficacy of convalescent plasma and plasma-based products in a subgroup of immunocompromised patients with iatrogenic B-cell depletion, showing significant clinical improvement and rapid viral clearance following plasma administration.

CLINICAL IMMUNOLOGY (2021)

Add to Collection

Review Immunology

Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia

Khalaf Kridin et al.

AUTOIMMUNITY REVIEWS (2020)

Add to Collection

Article Allergy

Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan

Xiaochen Li et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

Add to Collection

Editorial Material Medicine, General & Internal

Covid-19: risk factors for severe disease and death

Rachel E. Jordan et al.

BMJ-BRITISH MEDICAL JOURNAL (2020)

Add to Collection

Article Hematology

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Francesco Passamonti et al.

LANCET HAEMATOLOGY (2020)

Add to Collection

Review Cardiac & Cardiovascular Systems

The Relationship of COVID-19 Severity with Cardiovascular Disease and Its Traditional Risk Factors: A Systematic Review and Meta-Analysis

Kunihiro Matsushita et al.

GLOBAL HEART (2020)

Add to Collection

Letter Medicine, General & Internal

Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host

Bina Choi et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Multidisciplinary Sciences

Comparison of Antiviral Activity between IgA and IgG Specific to Influenza Virus Hemagglutinin: Increased Potential of IgA for Heterosubtypic Immunity

Mieko Muramatsu et al.

PLOS ONE (2014)

Add to Collection

Review Allergy

Rituximab: Beyond simple B cell depletion

A. Kessel et al.

CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2008)

Add to Collection

Review Medicine, General & Internal

Drug therapy: Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma

Bruce D. Cheson et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

Article Immunology

B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny

Jennifer H. Anolik et al.

CLINICAL IMMUNOLOGY (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.